Kifa Therapeutics is a biotechnology company developing highly selective, disease-modifying therapies for Parkinson’s disease and related neurodegenerative disorders. The company’s core expertise is in small-molecule inhibitors that specifically target the G2019S mutation in LRRK2-the most common genetic cause of familial Parkinson’s. Kifa is advancing two distinct series of G2019S-LRRK2 inhibitors, each showing over 150-fold selectivity for the mutant protein versus wild-type, with strong brain penetration and reduced off-target toxicity. The team combines deep experience in neurodegenerative biology, medicinal chemistry, and translational drug development, supported by a robust intellectual property portfolio. With a focus on biomarker-driven, rational drug design, Kifa is positioned as a leader in next-generation LRRK2-targeted therapeutics for Parkinson’s disease.